mRNA-engineered CAR mononuclear cell therapy enters the clinic

News

mRNA-engineered CAR mononuclear cell therapy enters the clinic

mRNA-engineered CAR mononuclear cell therapy enters the clinic: Cell manufacturing process takes just one day.

On May 12, Myeloid Therapeutics announced that its investigational therapy MT-101 has completed the first patient dosing in a Phase 1/2 clinical trial in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).

MT-101 is a CAR-monocyte (CAR-M) therapy engineered using mRNA.

It targets CD5, a cell surface receptor expressed in a variety of T-cell cancers. The press release noted that this is the first patient administration of an mRNA-engineered CAR mononuclear cell therapy.

Cell therapy represented by CAR-T cells has achieved remarkable results in the treatment of blood cancers.

However, autologous CAR-T therapy still faces multiple challenges, including the ineffective treatment of solid tumors and the complex manufacturing process.

Myeloid’s technology platform is designed to engineer myeloid cells in the human body into cancer-fighting therapies. Myeloid cells are part of the human innate immune system. They not only have the ability to recognize and phagocytose cancer cells, but also regulate downstream immune responses.

In the treatment of solid tumors, how to deliver cell therapy to tumor lesions throughout the body is an urgent challenge to be solved.

Myeloid cells frequently migrate from the blood to solid tumors or to sites of inflammation, a feature that promises to help address cell therapy delivery challenges.

At the 10th WuXi AppTec Global Forum, Dr. Debora Barton, Chief Medical Officer of Carisma Therapeutics, also said that for the treatment of solid tumors, it is meaningful to explore CAR macrophages, and engineered monocytes may be An effective way to improve the efficiency of CAR macrophage manufacturing (both macrophages and monocytes belong to myeloid cells).

MT-101 is a cell therapy produced by Myeloid using mRNA to engineer monocytes. Most monocytes in the blood differentiate into macrophages after migrating into tissues.

By expressing a CD5-targeting chimeric antigen receptor on the surface of monocytes, MT-101 can target and phagocytose tumor cells in peripheral tissues.

The press release notes that Myeloid’s therapeutic manufacturing process can produce CAR monocytes in just one day.

mRNA-engineered CAR mononuclear cell therapy enters the clinic: Cell manufacturing process takes just one day.

Characteristics of the myeloid cell therapy technology platform (Image source: Myeloid’s official website)

In this clinical trial, the first patient to complete dosing was treated for 28 days with no dose-limiting toxicity, no cytokine release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome.

“MT-101 took just 18 months from conception and preclinical proof-of-concept to first patient dosing. Importantly, this is the first engineered monocyte therapy delivered to a patient.” Chief Executive Officer, Myeloid “We are optimistic about the impact of this R&D program on patients with peripheral T-cell lymphoma,” said Dr. Daniel Getts.

References:

[1] Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans. Retrieved May 11, 2022, from https://www.prnewswire.com/news-releases/myeloid-therapeutics-doses-first-patient-with-mt-101-in-the-imagine-phase-12-clinical-study-marking-the-first-ever-dosing-of-an-mrna-engineered-car-monocyte-to-humans-301544958.html

mRNA-engineered CAR mononuclear cell therapy enters the clinic: Cell manufacturing process takes just one day.

(source:internet, reference only)

Disclaimer of medicaltrend.org